Sponsor pipeline

Greenwich LifeSciences, Inc. clinical trial pipeline

Get alerts when Greenwich LifeSciences, Inc.'s trials change

1 active trials 1 recruiting 1 Phase 3 1 disease areas 3 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-08-07
Primary completion pushed: 2026-12 → 2031-12
Enrollment increased: 750 → 2250 participants
Completion pushed: 2026-12 → 2031-12
NCT05232916 Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 +… · Phase 3

Active trials by phase

Phase 3
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT05232916 Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 +… Breast Cancer Recruiting 2026-08-06

Disease areas by active trials

Breast Cancer (1)

Get alerts when Greenwich LifeSciences, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free